Arcturus Therapeutics (ARCT) Misses Q2 EPS by 130c, misses on revenue

Arcturus Therapeutics (NASDAQ: ARCT) reported Q2 EPS of ($1.98), $1.30 worse than the analyst estimate of ($0.68). Revenue for the quarter came in at $10.52 million versus the consensus estimate of $28.38 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• ACCO Brands to buy European peripherals brand Trust for ~$100M revenue
• Marpai, Inc. (MRAI) Misses Q2 EPS by 18c